March 5, 2009 – Fifty patients who have undergone stereotactic body radiotherapy (SBRT) at Temple University have doubled their chances of surviving early stage lung cancer - and without the conventional radiation regimen or surgery.

Doctors in the Radiation Oncology Department at the university say the technique not only improves a person's odds of surviving early stage lung cancer but may reduce the need for future surgeries.

"This is a big trend in radiation oncology for early stage lung cancer patients who either can't undergo surgery or refuse it," said Curtis Miyamoto, M.D., chair and professor of the department of radiation oncology at the School of Medicine. "With the success of this technique, we're now questioning whether we'll even be doing surgeries on these patients in the future."

SBRT requires only three to eight treatments for lung cancer, not 35 in the typical case of radiation therapy. Although both traditional treatments and SBRT methods involve radiation, SBRT administers large, highly precise doses instead of multiple smaller doses.

But perhaps the most important advantage of SBRT is its effectiveness: Patients who refuse or cannot receive conventional treatments for their lung cancer face a median survival range of nine months. For those who undergo SBRT, the median survival range is more than 32 months. And depending on the size and seriousness of the tumor, the two-year disease free survival, or cure rate through SBRT increases to approximately 81 percent and can reach up to 98 percent, according to findings in the International Journal of Radiation OncologyBiologyPhysics. The cure rate with conventional radiation is closer to 35 percent; SBRT doubles the odds of surviving early stage lung cancer and can actually cure at least half of the patients.

"Such high survival rates are equivalent to other techniques, like invasive surgery, but you don't have to go under the knife," says Miyamoto. "I think the big thing the patient notices is it's all done very quickly and the results are impressive."

For more information: www.temple.edu


Related Content

News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Stereotactic Body Radiation Therapy (SBRT)

October 1, 2023 — Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted ...

Time October 01, 2023
arrow
News | Radiation Oncology

May 23, 2023 — ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that ...

Time May 23, 2023
arrow
News | Quality Assurance (QA)

March 16, 2023 — RTsafe, a leading provider of quality assurance products and services in stereotactic radiosurgery ...

Time March 16, 2023
arrow
News | Radiation Oncology

February 17, 2023 — Derry Crighton, a father of three from Scotland, says the Elekta Esprit radiosurgery system used to ...

Time February 17, 2023
arrow
News | Radiation Therapy

August 23, 2022 — Elekta announced that it has received CE mark for its Elekta Esprit, a new Leksell Gamma Knife ...

Time August 23, 2022
arrow
News | Radiation Therapy

March 15, 2022 — Above a certain size, individual brain metastases are often surgically removed with the help of ...

Time March 15, 2022
arrow
Sponsored Content | Videos | Radiation Therapy

Elekta’s latest linear accelerator, Harmony, is designed to provide a productive and versatile radiotherapy solution for ...

Time February 16, 2022
arrow
News | Radiation Oncology

January 27, 2022 — New guidelines for treating cancers that have spread to the brain are poised to improve care for ...

Time January 27, 2022
arrow
Videos | Radiation Therapy

The Elekta Harmony radiotherapy system gained FDA clearance in the summer of 2021 and was on display for the first time ...

Time November 17, 2021
arrow
Subscribe Now